BIIB - Biogen Inc.
| Previous Close | 332.87 |
| Open | 330.83 |
| Bid | 333.56 x 800 |
| Ask | 333.69 x 900 |
| Day's Range | 330.83 - 335.93 |
| 52 Week Range | 249.17 - 388.67 |
| Volume | 340,459 |
| Avg. Volume | 1,318,009 |
| Market Cap | 65.738B |
| Beta (3Y Monthly) | 1.74 |
| PE Ratio (TTM) | 15.49 |
| EPS (TTM) | 21.58 |
| Earnings Date | Apr 22, 2019 - Apr 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 385.63 |
- Zacks•4 days ago
Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.
Motley Fool•5 days agoAlkermes Plc (ALKS) Q4 2018 Earnings Conference Call Transcript
ALKS earnings call for the period ending December 31, 2018.
- Zacks•5 days ago
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
- Zacks•11 days ago
Top Research Reports for Visa, Charter Communications & Biogen
Top Research Reports for Visa, Charter Communications & Biogen
Bloomberg•12 days agoBiogen Sheds $5 Billion of Value as Drug Challenge Vexes Street
The decline was triggered by a Patent Trial and Appeal Board (PTAB) decision late Wednesday to consider Mylan NV’s challenge to a Biogen patent covering Biogen’s multiple sclerosis drug. The patent is critical in extending the medicine’s exclusivity into the next decade, and the PTAB’s ruling raises concerns about Tecfidera estimates, UBS analyst Carter Gould wrote in a note.
- Barrons.com•12 days ago
Biogen Stock Slips on a Setback in a Patent Dispute With Mylan
Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday.
- Zacks•15 days ago
Alkermes Sinks as FDA Refuses to Approve Depression Drug
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
- Motley Fool•18 days ago
6 Biotech Stocks to Watch Now
Here are six stocks that could pop or drop in 2019 based on these fast-approaching catalysts.
- Simply Wall St.•18 days ago
How Should You Price Biogen Inc.’s (NASDAQ:BIIB) Stock?
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. Knowing which valuation model to use for financial Read More...
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of BIIB earnings conference call or presentation 29-Jan-19 1:00pm GMT
Q4 2018 Biogen Inc Earnings Call
- Barrons.com•20 days ago
Biotech Giants Amgen and Biogen Fall on Earnings, Alzheimer’s News
Big biotech stocks are having a bad day Wednesday, following muted guidance from (AMGN) (AMGN) and downbeat news about potential Alzheimer’s treatments from a rival of (BIIB) (BIIB). It’s a downbeat day for Amgen and Biogen, although that hasn’t hurt their smaller peers much. Amgen took a hit after reporting fourth-quarter earnings.
- Motley Fool•21 days ago
Biogen Inc (BIIB) Q4 2018 Earnings Conference Call Transcript
BIIB earnings call for the period ending December 31, 2018.
- Zacks•21 days ago
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
- Zacks•21 days ago
Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4
Biogen (BIIB) beat estimates both for earnings and sales in Q4. Its newest drug Spinraza performed well in the quarter.
- Zacks•21 days ago
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
Style Box ETF report for FLQL
- Baystreet•21 days ago
Strong Start for TSX
Equities in Canada’s largest centre opened higher on Tuesday as energy shares were buoyed by higher ...
- Investing.com•21 days ago
Biogen Inc Earnings, Revenue beat in Q4
Investing.com - Biogen Inc (NASDAQ:BIIB) reported fourth quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
- CNBC•22 days ago
Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reports
Biotech stocks are on a roll so far this year. With Amgen, Biogen, and Celgene all set to report earnings this week, here's what Baird biotech analyst Brian Skorney says investors should be watching.
- Zacks•22 days ago
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
- Zacks•26 days ago
What's Behind the Biotech ETF Rally to Start 2019?
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
- Zacks•29 days ago
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
- Zacks•29 days ago
Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?
While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.
